Retrospective analysis of epirubicin, cisplatin, 5-fluorouracil(ECF) in refractory pancreatic cancer after gemcitabine-based chemotherapy
의약학 > 내과학
GukJinLee , MyungAhLee , HeeYeonLee , JiHyungHong , InSeokLee , TaeHoHong , YungKyungYoo
대한내과학회 추계학술발표논문집 2011년, 제2011권 제1호, 287(총1페이지)
42846724.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Background: The standard treatment of recurrent or unresectable pancreatic cancer is gemcitabine-based chemotherapy, combination with tarceva or capecitabine. However, there is no effective regimen for patients who have progressive disease after these drugs. We performed retrospective analysis to evaluate the efficacy and toxicity of ECF regimen for the patients who had good performance status but progressive disease after previous chemotherapy in recurrent or unresectable pancreatic cancer. Method: Between October 2008 and June 2011, we retrospectively reviewed twenty one patients who had an initially metastatic disease or recurrent disease after operation. All patients had progressive disease after the gemcitabine-based chemotherapy and a good performance status(ECOG≤2). The treatment schedules were as follows: 5-fluorouracil 1000 mg/m2, day 1-3, Cisplatin 60 mg/m2, day 1, and Epirubicin 50 mg/m2, day 1, repeated every 21 days. Result: Among the 21 patients, male was 13 patients and female was 8 patients. Median age was 59, and median ECOG P.S was 1. They were treated with gemcitabine/tarceva, gemcitabine/capecitabine,gemcitabine/5-FU or gemcitabine monotherapy as first line treatment. Median number of cycle was 2(range: 1-8). Six patients had stable disease, and two patients had partial response (overall response rate: 10%). The median progression free survival was 2.3 months, and the median overall survival was 4.3 months. In hematologic toxicity, there were 48% grade 3/4 neutropenia, and 10% thrombocytopenia. In non-hematologic toxicity, there were 5% grade 3 nausea/vomiting, and fatigue. There was no treatment-related death. Conclusion: ECF regimen have been used for the refractory pancreatic cancer because this drugs was commonly used before the development of gemcitabine. In the present study, ECF showed little efficacy with the high rate of grade 3/4 neutropenia. Newer chemotherapeutic regimen should be developed for the patients with refractory pancreatic cancer but good performance status.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.